An open-label, crossover study to compare different formulations and evaluate effect of food on pharmacokinetics of pimitespib in patients with advanced solid tumors
出版年份 2022 全文链接
标题
An open-label, crossover study to compare different formulations and evaluate effect of food on pharmacokinetics of pimitespib in patients with advanced solid tumors
作者
关键词
-
出版物
INVESTIGATIONAL NEW DRUGS
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-08-06
DOI
10.1007/s10637-022-01285-9
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Randomized, double-blind, placebo (PL)-controlled, phase III trial of pimitespib (TAS-116), an oral inhibitor of heat shock protein 90 (HSP90), in patients (pts) with advanced gastrointestinal stromal tumor (GIST) refractory to imatinib (IM), sunitinib (SU) and regorafenib (REG).
- (2021) Yoshitaka Honma et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520
- (2019) Remy B. Verheijen et al. Targeted Oncology
- First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors
- (2019) Akihiko Shimomura et al. MOLECULAR CANCER THERAPEUTICS
- Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial
- (2019) Toshihiko Doi et al. EUROPEAN JOURNAL OF CANCER
- High expression of HSP90 is associated with poor prognosis in patients with colorectal cancer
- (2019) Shuming Zhang et al. PeerJ
- Targeted cancer therapy through 17-DMAG as an Hsp90 inhibitor: Overview and current state of the art
- (2018) Hassan Mellatyar et al. BIOMEDICINE & PHARMACOTHERAPY
- Food, gastrointestinal pH, and models of oral drug absorption
- (2017) Ahmad Y. Abuhelwa et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- HSP90 promotes cell glycolysis, proliferation and inhibits apoptosis by regulating PKM2 abundance via Thr-328 phosphorylation in hepatocellular carcinoma
- (2017) Qiuran Xu et al. Molecular Cancer
- Acquired resistance to 5-fluorouracil via HSP90/Src-mediated increase in thymidylate synthase expression in colon cancer
- (2015) Ji-Young Ahn et al. Oncotarget
- A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors
- (2013) M. W. Saif et al. CLINICAL CANCER RESEARCH
- High Expression of Heat Shock Protein 90 Is Associated with Tumor Aggressiveness and Poor Prognosis in Patients with Advanced Gastric Cancer
- (2013) Jiahong Wang et al. PLoS One
- A Heat-Shock Protein Axis Regulates VEGFR2 Proteolysis, Blood Vessel Development and Repair
- (2012) Alexander F. Bruns et al. PLoS One
- Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas
- (2011) Jenny Welander et al. ENDOCRINE-RELATED CANCER
- Multicenter Phase II Trial of the Heat Shock Protein 90 Inhibitor, Retaspimycin Hydrochloride (IPI-504), in Patients With Castration-resistant Prostate Cancer
- (2011) William K. Oh et al. UROLOGY
- Reactive oxygen species mediate hepatotoxicity induced by the Hsp90 inhibitor geldanamycin and its analogs
- (2010) Yuval Samuni et al. FREE RADICAL BIOLOGY AND MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started